Legend Biotech (LEGN) experienced an 18% surge on Monday, driven by two positive analyst recommendations. RBC Capital’s Leonid Timashev set a price target of $62 per share, while H.C. Wainwright’s Mitchell Kapoor targeted $50, motivated by the encouraging progress of Legend’s pipeline and the recent Eli Lilly acquisition of Kelonia Therapeutics. The excitement around Legend’s CAR-T therapy developments, along with promising trial data on its CD19/CD20 targets, positions it as a notable biotech to watch.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/investing/2026/04/20/why-legend-biotech-stock-crushed-the-market-on-mon/
